Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on September 25, 2017. The filing reports a corporate action regarding the voluntary delisting of the Company's common stock from the NYSE American and its subsequent transfer to the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the change in stock exchange listing and does not contain financial performance data.
Material Changes
- Listing Transfer: The Company notified the NYSE American of its intention to voluntarily delist its common stock.
- New Listing Venue: The stock will transfer to the Nasdaq Global Select Market.
- Trading Symbol: The common stock will continue to trade under the symbol "TXMD."
- Effective Dates: Trading on the NYSE American is expected to cease at market close on October 8, 2017, with trading on Nasdaq commencing on October 9, 2017.
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.1) announcing the move to Nasdaq. The document states that the information provided in Item 7.01 and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific financial guidance, risk factors, or contingencies related to the Company's operations are detailed in this specific filing text.
Investor Verification Checklist
- Confirm the exact trading halt time on the NYSE American on October 8, 2017.
- Verify the opening trading time on the Nasdaq Global Select Market on October 9, 2017.
- Ensure brokerage accounts are updated to reflect the new exchange listing for the "TXMD" symbol.
- Review the full text of the press release (Exhibit 99.1) for any additional context regarding the strategic rationale for the move.